Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market
完整報告名稱與涵蓋範圍
Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Size, Share & Trends Analysis Report, By Product Type (saRNA Vaccines (Infectious Disease), saRNA Cancer Immunotherapies, saRNA Protein Replacement and Other Therapeutics, saRNA Platform Technologies and Licensing), By Replicon Design (Alphavirus-Derived Replicons, Trans-Amplifying and Split Replicon Systems, Engineered and Non-Alphavirus Replicons), By Development Stage (Approved and Commercial, Clinical, Preclinical), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The self-amplifying RNA vaccines and therapeutics market covers products that encode a viral replicase alongside the antigen or therapeutic protein so that RNA replicates within cells, including approved and pipeline infectious disease vaccines, cancer immunotherapies, protein replacement therapeutics and the platform technologies licensed to develop them. Conventional non-replicating mRNA products and the underlying raw material and manufacturing service markets are excluded.
The first approvals of a self-amplifying COVID-19 vaccine in Japan and Europe established regulatory precedent and demonstrated durable immune responses at a fraction of conventional mRNA doses, which lowers cost per dose, eases manufacturing capacity constraints and may reduce reactogenicity. Developers are now advancing seasonal and pandemic influenza, RSV and combination vaccines, oncology programs that benefit from sustained antigen expression and therapeutics requiring prolonged protein production, while trans-amplifying and engineered replicon designs address size, innate immune activation and delivery challenges. Manufacturing of long RNA constructs, purification of intact replicons and lipid nanoparticle compatibility are the principal technical considerations, and platform licensing has become a revenue source in its own right.
Japan, the United States and Europe lead commercialisation and development, with India and China building domestic self-amplifying programs. Competition involves replicon platform pioneers, vaccine companies with licensed platforms and RNA manufacturers offering saRNA-ready capabilities.
The InsightAce study includes revenue forecasts in US$ for all product type, replicon design, development stage and end user and regional segments across 2026-2035, segment-level trend analysis, competitive positioning assessment and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Snapshot
Chapter 4. Global Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. Product Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product Type:
5.2.1. saRNA Vaccines (Infectious Disease)
5.2.2. saRNA Cancer Immunotherapies
5.2.3. saRNA Protein Replacement and Other Therapeutics
5.2.4. saRNA Platform Technologies and Licensing
Chapter 6. Market Segmentation 2: By Replicon Design Estimates & Trend Analysis
6.1. Replicon Design & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Replicon Design:
6.2.1. Alphavirus-Derived Replicons
6.2.2. Trans-Amplifying and Split Replicon Systems
6.2.3. Engineered and Non-Alphavirus Replicons
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Approved and Commercial
7.2.2. Clinical
7.2.3. Preclinical
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Vaccination Programs and Clinics
8.2.2. Hospitals and Treatment Centers
8.2.3. Pharmaceutical Licensees
Chapter 9. Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Arcturus Therapeutics Holdings Inc.
11.2. CSL Seqirus
11.3. Quantoom Biosciences
11.4. TriLink BioTechnologies (Maravai LifeSciences)
11.5. Replicate Bioscience, Inc.
11.6. VLP Therapeutics Japan
11.7. Elicio Therapeutics, Inc.
11.8. Ziphius Vaccines
11.9. Gennova Biopharmaceuticals Limited
11.10. Chimeron Bio
11.11. Pfizer Inc.
11.12. BioNTech SE
11.13. Novartis AG
11.14. Imperial College London (VaxEquity)
11.15. Daiichi Sankyo Company, Limited
圖表清單 List of Tables & Figures
Table 1. Global Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Revenue Forecast by Product Type, 2026-2035 (US$ Mn)
Figure 1. Global Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Segmentation Overview
Table 2. Global Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Revenue Forecast by Replicon Design, 2026-2035 (US$ Mn)
Figure 2. Global Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Share by Product Type, 2026 & 2035
Table 3. Global Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. Dose, Durability and Manufacturing Comparison: Self-Amplifying Versus Conventional mRNA
Table 4. Global Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Share by Replicon Design, 2026 & 2035
Table 5. North America Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. saRNA Pipeline by Indication, Replicon Design and Phase, 2026
Table 6. Europe Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Growth Opportunity Analysis
Table 7. Asia Pacific Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Regulatory Approval Precedents and Platform Licensing Structures for saRNA
Table 8. Latin America Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Participants
Table 9. Middle East & Africa Self-Amplifying RNA (saRNA) Vaccines & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們